Mr. Hampton joined Currax Pharmaceuticals in April of 2019 as President & CEO and serves on its board of directors. Prior to joining Currax, Mr. Hampton served as executive vice president, primary care business unit for Horizon Pharmaceuticals (HZNP), a public biopharmaceutical company. In this role he was tasked with leading the forward-looking strategy, as well as establishing operational goals for the business. Previously, Mr. Hampton served as executive vice president, global orphan business unit and international operations for Horizon Pharmaceuticals. He has more than 25 years of experience as a successful executive in the pharmaceutical and biotech field on both a national and international scale including specific expertise in rare disease (ACTIMMUNE, RAVICTI, PROCYSBI), autoimmune (HUMIRA), primary care, orthopedic (CELEBREX), diabetes (BYETTA), anti-infectives and cardiovascular spaces. This includes roles of increasing responsibility in sales, marketing and operations at G.D. Searle, Abbott, (now AbbVie), Amylin and Horizon Pharmaceuticals.

Hampton earned his Bachelor of Science from Miami University in Oxford, Ohio. He serves on the board of Amyrt Pharmaceuticals (AMYT.L), a biopharmaceutical company. Additionally, he serves on the board of IMAC (NASDAQ: IMAC) regeneration medical centers.

Dr. Michael Kyle joined Currax Pharmaceuticals LLC in 2022 where he serves as SVP, Chief Medical Officer. As a member of the Currax Senior Leadership Team, Michael leads and manages all aspects of clinical development, clinical operations, medical affairs, safety and pharmacovigilance, and regulatory affairs.

Prior to joining Currax Pharmaceuticals, Michael served as Head of Development at China’s largest pharmaceutical company, Jiangsu Hengrui Pharmaceuticals, where he led and managed all aspects of clinical development, medical, and regulatory affairs. Previously, Michael served in clinical development and medical affairs roles at Pfizer, including as Chief Medical Officer of Consumer Health, and as VP, Head of Global Clinical Sciences and Operations for the Upjohn division.

Michael brings a diverse set of skills, having served as Medical Director at Radiant Research, where he led the clinical trial center, successfully conducting nearly 250 (Phase I-IV) clinical trials across 15+ therapeutic areas including vaccines, diagnostics, and devices. Additionally, he served as a practicing family physician in private practice for 12 years, as the Medical Director at Assurant Health, and at Loyola Medical School, as an Independent Faculty Teaching Attending.

Michael earned his Bachelor of Science in Psychology from Loyola University and his Medical Degree from Rush Medical College in Chicago. He is a board-certified family physician and completed his residency training at West Suburban Family Medicine Residency Program in Oak Park/River Forest, IL.

Hope Mueller joined Currax Pharmaceuticals LLC in February 2022 as the SVP, Corporate Development and Strategy, bringing over 25 years of healthcare leadership experience directing corporate strategy, business development, continuous improvement, communications, operations, and quality.

Prior to joining Currax, Hope served in various VP roles at Horizon Therapeutics, including VP of Quality, VP of Continuous Improvement, VP of Quality and Integration, and VP of R&D Program and Project Management. Hope transitioned from Catalent to Crealta Pharmaceuticals (acquired by Horizon) to lead Quality, Operations, and all vendor and contract manufacturing oversight as the VP of Quality Assurance.

At Catalent, Hope scaled her level of responsibility, first as the Director of Analytical Quality, then as the Director Manufacturing and Customer Quality, and finally tackled the role of Site Head of Quality, with over 120 personnel, 38 Blow-Fill-Seal (BFS) filling lines, hundreds of products, and 30+ contract manufacturing clients. At Baxter Healthcare, in five years, she ascended from a Microbiology Analyst, through Supervisor and Manager roles, to a Senior Manager of Quality Improvement, where she drove process improvements across eight global sites.

Hope received her Bachelor of Science degree from Indiana University Bloomington in Biology, and her MBA from Northwestern University Kellogg School of Management. She is the Founder and President of Hunter Street Charity, an organization that provides support for children and families during critical times of need.

Aaron Baratta joined Currax Pharmaceuticals LLC in 2019 as VP, Sales, bringing a successful track record of building sales infrastructures and elite sales teams from the ground up at start-up pharmaceutical companies. He has consistently achieved blockbuster sales growth by creating and executing winning strategies, and by navigating today’s evolving managed care challenges.

Prior to joining Currax Pharmaceuticals, Aaron assumed increasing levels of responsibility at Horizon Pharma from 2012 to 2017, culminating in serving as group vice president, managing all aspects of sales and operations with a sales budget of $100M+. Under his leadership, net revenue grew from $18.8M to $1B+ in 5 years, with market cap increasing from $200M to $5B, and the stock price rising from $2 to $36. As a result, Aaron was a two-time recipient of the prestigious “Chairman’s Award.”

From 2006 to 2011, Aaron served as area sales director/regional manager at Victory Pharma. During this time, Aaron built and trained an entire sales force and drove annual sales from $13M in 2006 to over $215M in 2011, increasing the sales team from 40 to 145. Of note was his management of the relaunch of NAPRELAN, which saw sales increase from $10M to over $75M in 5 years, with an increase in RX volume of 17,000 to 101,000. Quarterly net profitability increased by over 300%. Prior to Victory, Aaron helped build Cornerstone BioPharma and Biovail Pharmaceuticals, launching new sales processes and building teams from the ground up.

Aaron received his B.A. in Marketing from Arizona State University.

Aaron Chesnut joined Currax Pharmaceuticals LLC in 2021 as the VP, Technical Operations, bringing with him more than 20 years of strategic and operational experience in global biopharmaceutical, medical device, biotech, and clinical research. He has implemented best practices in operations, engineering, quality, validation, clinical trials, manufacturing, laboratory testing, supply chain, and regulatory affairs. In addition, Aaron has managed the successful development, tech transfer, licensure, and operations of numerous drug and biologic products.

Aaron has deep experience in technical operations including serving as Site Head of Quality at Allergan’s Biologic Drug Substance BLI facility for the manufacture of BOTOX®. Additionally, he led the design, build, qualification, and licensure of pharmaceutical manufacturing facilities, including Genentech’s Oceanside Drug Substance/API facility and their Oregon Aseptic Drug Product facility.

Previous to Currax Pharmaceuticals, Aaron was the Owner and Principal Consultant for Foundation Solutions GxP, where he led a team of senior consultants for the startup, tech transfer, and FDA licensure of biosimilar products manufactured at their CMO facility in South Korea. Aaron has served in senior roles at Prolacta Bioscience as Director of Quality Control, as Senior Director of Quality & MSAT at PMI BioPharma Solutions, and served in Senior Engineering roles at BiogenIDEC (acquired by Genentech), and Baxter BioScience.

Prior to entering the pharmaceutical industry, Aaron spent three years with NASA working with a research team that investigated the biologic impact of ionizing radiation to the human body to support deep space travel.

Aaron received his Bachelor of Science in Biochemistry from the University of California.

Laura Lustig joined Currax Pharmaceuticals LLC in January 2020 as VP, Human Resources. She brings 25+ years of experience leading global human resources, building high-performing teams and strong cultures, leading organizational change strategies, and identifying, recruiting, and retaining first-class talent.

Prior to joining Currax Pharmaceuticals LLC, Laura served as VP of Human Resources for Cardiac Science, a global leader in the design, manufacturing, and marketing of automated external defibrillators (AEDs). Previously, Laura served as a senior HR leader for the flagship operating company at Danaher Corporation (DHR), a Fortune 200 company, global life sciences and diagnostics innovator. Laura led the implementation of Danaher Business System for HR programs and business initiatives exceeding expectations.

Additionally, Laura served as VP of Human Resources for the public biopharmaceutical company Horizon Therapeutics (HZNP), leading HR through significant growth and multiple integrations as market cap increased from $225M to $5B during her time, staff grew from 200 to 900, and the company built out offices in the U.S., Ireland, and Germany. Laura also served in senior roles at Baxter International and Fenwal, Inc., a global technology subsidiary of Baxter, where Laura led the complex HR and statutory transition requirements for the carve-out and sale to private equity firm TPG, encompassing 30+ countries and an aggressive 90-day schedule.

Laura received her Bachelor of Science in Public Affairs, Personnel Management & Labor Relations from Indiana University.

Jason James joined Currax Pharmaceuticals LLC in 2022 as VP, Finance, Commercial Operations, and Analytics, bringing with him over 20 years of proven leadership in finance, commercial and digital analytics, machine learning, and statistics in healthcare.

Prior to joining Currax Pharmaceuticals, Jason served as VP of Commercial Operations for Cognoa, a software as medical device (SaMD) start-up with June 2021 FDA authorization for an Autism Spectrum Disorder machine learning-enabled digital diagnostic aid. There, he established the core commercial infrastructure and the go-to-market playbook inclusive of core field sales processes, sales operations, business analytics, payor segmentation, coding and reimbursement strategy. Previously, Jason served as VP of Business Analytics and Operations for Zealand Pharma, where he was one of the first U.S. commercial leadership hires for this Denmark-headquartered peptide development leader, reporting to the U.S. President.

Earlier positions include serving as VP of Global Business Analytics and Sales Operations for Avexis, Inc. (acquired by Novartis), and SVP of Commercial Operations and Analytics for Catalyst Pharmaceuticals, where he established the pre-and post-launch analytics strategy and commercial infrastructure supporting the successful launch of FIRDAPSE®, with over $100M in revenue in its first year and 400 patients enrolled. Additional roles include Group VP of Corporate Analytics for Horizon Pharma, and Finance, Analytics, Forecasting and Commercial Assessment senior roles at Lundbeck and Abbott Laboratories.

Jason received his Bachelor of Science in Finance from the Indiana University Kelley School of Business, and his Master of Professional Studies in Analytics from Northeastern University.

Colton Cline joined Currax Pharmaceuticals LLC in August 2021 and has assumed increasing levels of leadership responsibility. Colton was appointed to serve as VP, Assoc. General Counsel and leads the legal, contracts and compliance functions.

Prior to joining Currax Pharmaceuticals, Colton served as Senior Associate General Counsel at Wellpath, the premier provider of localized, high-quality, compassionate care to vulnerable patients in challenging clinical environments, with nearly 15,000 clinicians and professionals across 37 states in the U.S. and Australia. In this role, Colton led the corporate governance and contracts function where his team negotiated and assisted in administration of contracts with local government, state, federal, and private parties. Colton also served as a regulatory and operations resource for clinicians and leadership in varied dynamic institutional healthcare settings.

Previously, Colton served as Assistant General Counsel for the Tennessee Department of Commerce and Insurance’s Securities Division and ultimately led the agency’s public procurement functions.

Colton received his Bachelor of Arts in Philosophy from Baylor University and a Doctor of Jurisprudence from Vanderbilt University Law School.